Impact of HER2-Low status in metastatic gastric cancer:A real-world retrospective cohort study.
Oncology
; 2024 Feb 14.
Article
em En
| MEDLINE
| ID: mdl-38354717
ABSTRACT
INTRODUCTION:
Information regarding HER2-low tumors in metastatic gastric cancer is sparse. Our aim here was to determine the frequency of low HER2 expression in metastatic gastric cancer and to compare the clinicopathological characteristics, survival, and treatment response of HER2-low patients with HER2-zero patients.METHODS:
All the data were collected retrospectively from computerized system of the hospital. We categorized the patients according to clinicopathological features, treatment responses, and survival in terms of HER2-low tumors and HER2-zero tumors.RESULTS:
Of 226 patients, 71 (31.4%) had low HER2 expression and 155 (68.6%) had zero HER2 expression. HER2-low tumors were detected more frequently in older patients and in low-grade tumors than HER2-zero tumors (69% vs 47.7%, P = 0.003, 16.9% vs 3.8%, P < 0.001). All patients received a first-line chemotherapy regimen. The disease control rate was not statistically different between both groups (40% vs 46.4%, P=0.11). The median survival was 12.05 (95% CI, 8.09-16.02) months in HER2-low patients, and 10.41 (95% CI, 8.52-12.3) months in HER20-zero patients with no statistical difference (P=0.73).CONCLUSION:
HER2-low metastatic gastric cancer has a higher rate of being low-grade than HER2-zero tumors. HER2-low metastatic gastric cancer is similar to HER2-zero in terms of chemotherapy response and survival.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article